Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV's pipeline of antimalarial drugs
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Malaria online course
Global health compound design webinars
Call for proposals
TPPs & TCPs
Learning resources for scientists
Project of the year award
Computational chemistry
R&D challenges
Access
Products & projects
Antimalarial drug availability
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Antimalarial drug toolkits
Artesunate injection dosage & administration
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
Access challenges
Partnering
The PDP model
Our partner network
Our donors
Current donors
Past donors
Donate to MMV
Intellectual property rights (IPR)
Clinical centre partners by country
Our impact
Milestones
Malaria stories from the field
Antimalarial drugs for children
Gender equity
Global health security
Antimicrobial resistance to antimalarials
Malaria and COVID-19
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
5 species of
Plasmodium
parasites
Lifecycle of malaria parasite
Malaria facts & statistics
Malaria treatment
History of antimalarial drugs
Newsroom
News & Press Releases
Audio
Media interviews
Speaking of Malaria podcast
Films
Infographics
Interviews
Image slideshows
Publications
Events
MMV Open
The Global Health Priority Box
About the Global Health Priority Box
Supporting information
Request the Global Health Priority Box
Terms & conditions
Malaria
Libre
Malaria
Libre
open innovation platform
Participate in Malaria
Libre
Malaria
Libre
data repository
MMVSola
About MMVSola
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
COVID Box
About the COVID Box
Supporting information
COVID Box terms and conditions
Archived projects
Pathogen Box
Malaria Box
MMV Open Team
Contact us
Home
Newsroom
Publications
Publications
Filter
Category
Pathogen Box article
Scientific article
Journal
ACS Infectious Diseases
Bioorganic Chemistry
Clinical Microbiology Reviews
European Biopharmaceutical Review
Frontiers in Microbiology
International Journal for Parasitology
International Journal for Parasitology: Drugs and Drug Resistance
PLOS Neglected Tropical Diseases
Parasites & Vectors
Parasites and Vectors
Authors (MMV)
Abena Poku-Awuku
Adam Aspinall
Andrea Lucard
André-Marie Tchouatieu
Anne Claire Marrast
Belen Tornesi
Benoit Laleu
Brice Campo
Cristina Donini
Céline Audibert
Danielle Sessa
David Reddy
Delphine Baud
Didier Leroy
Doreen Yomoah
Elizabeth Poll
Elodie Chenu
Elodie Jambert
Emilie Escoffier
Empty (11500)
Empty (12273)
Empty (12377)
Empty (12475)
Empty (12500)
Empty (13668)
Empty (9261)
Empty (9275)
Empty (9293)
Empty (9340)
George Jagoe
Hans Rietveld
Hanu Ramachandruni
Helen Demarest
Isabelle Borghini-Fuhrer
James Duffy
Jeremy Burrows
Jörg Möhrle
Maud Majeres Lugand
Myriam El Gaaloul
Mélanie Rouillier
Nada Abla Geiser
Nada Araeipour
Nathalie Gobeau
Paul Willis
Pierre Hugo
Silvia Ferazzi
Stephan Duparc
Stephan Chalon
Stephen Brand
Sylvie Fonteilles-Drabek
Tim Wells
Wiweka Kaszubska
Zaira Rizopoulos
Search
24 found
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362
10 Oct 2022
Preliminary Structure-Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors of
Trypanosoma brucei brucei
04 Oct 2022
Exploring a Tetrahydroquinoline Antimalarial Hit from the Medicines for Malaria Pathogen Box and Identification of its Mode of Resistance as PfeEF2
21 Sep 2022
Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage
Plasmodium falciparum
, using a nano luciferase reporter read-out
21 Jul 2022
Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development
25 Mar 2022
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials
26 Aug 2021
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity
08 Aug 2021
The
Plasmodium falciparum
ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance
05 Jul 2021
Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as
Plasmodium
Cytoplasmic Prolyl-tRNA Synthetase Inhibitors
11 Jun 2021
Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series
13 May 2021
Actives from MMV Open Access Boxes? A suggested way forward
22 Apr 2021
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
Plasmodium falciparum
11 Mar 2021
Escaping from Flatland: Antimalarial Activity of sp
3
-Rich Bridged Pyrrolidine Derivatives
10 Nov 2020
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials
12 Dec 2019
Early Antischistosomal Leads Identified from in Vitro and in Vivo Screening of the Medicines for Malaria Venture Pathogen Box
16 Nov 2018
Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against
Schistosoma mansoni
15 May 2018
Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma
26 Apr 2018
Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates
15 Aug 2017
In vitro screening of the open source pathogen box identifies novel compounds with profound activities against
Neospora caninum
25 Jul 2017
Screening of the ‘Stasis Box’ identifies two kinase inhibitors under pharmaceutical development with activity against
Haemonchus contortus
05 Jul 2017
Assessing the anthelmintic activity of pyrazole-5-carboxamide derivatives against Haemonchus contortus
31 May 2017
Susceptibility Testing of Medically Important Parasites
26 Apr 2017
Identifying the need for new drugs – Opening doors
20 Mar 2017
Screening of the ‘Pathogen Box’ identifies an approved pesticide with major anthelmintic activity against the barber's pole worm
28 Jul 2016